An Open-Label, Multinational Study Of The Efficacy And Safety Of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2018
At a glance
- Drugs AVR RD 01 (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors AVROBIO
- 13 Nov 2018 According to a AVROBIO media release, the Company plans to provide further updates in the first quarter of 2019
- 01 Oct 2018 According to a AVROBIO media release, Enrollment continues in Phase 2 clinical trial and first patients 3-month results demonstrate AGA enzyme activity from AVR-RD-01 gene therapy in ERT-naive patient.
- 09 Aug 2018 According to a AVROBIO media release, the company has recently held a pre-IND meeting and is planning open a U.S. site for this study in 2019.